Meeting Coverage
AANEM
American Association of Neuromuscular & Electrodiagnostic Medicine
Changes in CAFS, ALSFRS-R scores comparable at 48 weeks
Latest AANEM Meeting Coverage
Insurance claims data show lower glucocorticoid usage at 1 year
Nipocalimab plus standard of care reduced IgG and was well tolerated
Differences between delandistrogene moxeparvovec and placebo emerge in secondary outcomes
Phase III trial met primary endpoint at 6 months
Topline phase III data show inebilizumab met primary endpoint
Small VA-based study saw promising short-term results with no adverse events
Subcutaneous formulation lowers relapse risk in debilitating autoimmune disorder
Benefits maintained after multiple treatment cycles
44% of treated patients with CIDP showed improvement after switching to riliprubart
Hospitalization dropped threefold, real-world data show
Findings suggest patients with SCLC are not screened for LEMS, despite their association